Thromb Haemost 2014; 111(01): 94-102
DOI: 10.1160/TH13-08-0666
Blood Coagulation, Fibrinolysis and Cellular Haemostasis
Schattauer GmbH

A non-interventional comparison of rivaroxaban with standard of care for thromboprophylaxis after major orthopaedic surgery in 17,701 patients with propensity score adjustment

Alexander G. G. Turpie
1   Department of Medicine, Hamilton Health Sciences, Hamilton, Ontario, Canada
,
Sylvia Haas
2   Institute for Experimental Oncology and Therapy Research, Technical University of Munich, Munich, Germany
,
Reinhold Kreutz
3   Institut für Klinische Pharmakologie und Toxikologie, Charité-Universitätsmedizin, Berlin, Germany
,
Lorenzo G. Mantovani
4   Dipartimento di Medicina Clinica e Chirurgia, Università degli Studi di Napoli Federico II, Naples, Italy
,
Cassandra W. Pattanayak
5   Harvard University Statistics Department (current address: Quantitative Analysis Institute, Wellesley College, Wellesley, Massachusetts, USA)
,
Gerlind Holberg
6   Bayer HealthCare AG, Berlin, Germany
,
Waheed Jamal
6   Bayer HealthCare AG, Berlin, Germany
,
André Schmidt
6   Bayer HealthCare AG, Berlin, Germany
,
Martin van Eickels
6   Bayer HealthCare AG, Berlin, Germany
,
Michael R. Lassen
7   Glostrup Hospital, Spine Center, Clinical Trial Unit, University of Copenhagen, Glostrup, Denmark
› Author Affiliations
Financial support: This study was sponsored by Bayer HealthCare Pharmaceuticals with support from Janssen Research and Development, LLC.
Further Information

Publication History

Received: 14 August 2013

Accepted after minor revision: 17 September 2013

Publication Date:
29 November 2017 (online)

Zoom Image

Summary

Rivaroxaban demonstrated superior efficacy and a similar safety profile to enoxaparin for the prevention of venous thromboembolism in the phase III RECORD programme in patients undergoing elective hip or knee replacement surgery. The XAMOS study investigated adverse events, including bleeding and thromboembolic events, in patients receiving rivaroxaban for thromboprophylaxis in routine clinical practice. XAMOS was a non-interventional, open-label cohort study in patients undergoing major orthopaedic surgery of the hip or knee (predominantly elective arthroplasty), in which rivaroxaban was compared with other pharmacological thromboprophylaxis. All adverse events were documented, including symptomatic thromboembolic and bleeding events. Crude and adjusted incidences based on propensity score subclasses were calculated and compared between the rivaroxaban and standard-of-care groups. A total of 17,701 patients were enrolled from 252 centres in 37 countries. Crude incidences of symptomatic thromboembolic events three months after surgery in the safety population were 0.89% in the rivaroxaban group (n=8,778) and 1.35% in the standard-of-care group (n=8,635; odds ratio [OR] 0.65; 95% confidence interval [CI] 0.49–0.87), and 0.91% and 1.31% (weighted) in the propensity score-adjusted analysis (OR 0.69; 95% CI 0.56–0.85), respectively. Treatment-emergent major bleeding events (as defined in the RECORD studies) occurred in 0.40% and 0.34% of patients in the rivaroxaban and standard-of-care groups in the safety population (OR 1.19; 95% CI 0.73–1.95), and in 0.44% versus 0.33% (weighted) in the propensity score-adjusted analysis (OR 1.35; 95% CI 0.94–1.93), respectively. This study in unselected patients confirmed the favourable benefit–risk profile of rivaroxaban seen in the RECORD programme.